Research programme: macrocyclic compounds - Bristol-Myers Squibb/Oncodesign
Latest Information Update: 28 Feb 2020
At a glance
- Originator Oncodesign Biotechnology
- Class Antineoplastics; Macrocyclic compounds; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Unspecified
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Cancer in France
- 28 Feb 2020 No recent reports of development identified for research development in Unspecified in France
- 05 Jan 2016 Oncodesign and Bristol-Myers Squibb agree to co-develop macrocyclic compounds for Cancer